Compounds / Metabolic / Semaglutide

Semaglutide

Semaglutide (GLP-1 Receptor Agonist)
MetabolicFDA ApprovedFDA: FDA-APPROVED (Ozempic: T2DM; Wegovy...

Overview

FDA-approved (Ozempic/Wegovy). STEP trials: 10–15% mean body weight reduction at 2.4 mg/week. Cardiovascular outcome benefits (SUSTAIN trials).

Mechanism of Action

GLP-1 receptor agonist. ~7-day half-life via albumin binding + DPP-4 resistance. Reduces appetite via CNS GLP-1 receptors. Slows gastric emptying. Glucose-dependent insulin secretion. 94% homology to native GLP-1.

Pharmacokinetics

Half-life
7 days
Peak (Tmax)
1 day
Cleared
~35 days

Molecular Profile

Molecular weight
4,113.64 Da
CAS number
910463-68-2
Type
GLP-1 receptor agonist
Length
31 amino acids
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-

Key Research Findings

10–15% weight loss (STEP trials); CV risk reduction; improved glycemic control; once-weekly dosing.

Published Research

PMC (2022)
Once-Weekly Semaglutide for Weight Management: Clinical Review
View source
NCBI Bookshelf
Semaglutide (StatPearls): pharmacology, dosing, adverse effects
View source

Related Metabolic Compounds

TirzepatideRetatrutideCagrilintideMazdutideBioglutideAOD-9604
Clinical Guidance

Research data is not a treatment plan. If you are considering Semaglutide, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Semaglutide? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals